Clinical data | |
---|---|
AHFS/ Drugs.com | International Drug Names |
Routes of administration | IV |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C19H17N5O2 |
Molar mass | 347.378 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
Nafamostat mesylate ( INN), a synthetic serine protease inhibitor, it is a short-acting anticoagulant, [1] and is also used for the treatment of pancreatitis. It also has some potential antiviral and anti-cancer properties. [2] Nafamostat is a fast-acting proteolytic inhibitor and used during hemodialysis to prevent the proteolysis of fibrinogen into fibrin. [3] The mechanism of action of Nafamostat is as a slow tight-binding substrate, trapping the target protein in the acyl-enzyme intermediate form, resulting in apparent observed inhibition. [4] [5]
It inhibits a large number of Lys/Arg specific serine proteinases, and is also a tryptase inhibitor, which is implicated in leaking blood vessels which is symptomatic of dengue hemorrhagic fever and of end-stage dengue shock syndrome. [6] It is available in a generic form already used for the treatment of certain bleeding complications in some countries, there are risks of severe complications such as: agranulocytosis, hyperkalemia, and anaphylaxis which must be weighed in non-emergency care. [7] In some countries, it used as a treatment for pancreatitis and pancreatic cancer.[ citation needed]
This drug has been identified as a potential therapy for COVID-19, [8] with clinical trials in Japan possibly set to begin in March 2020. [9] With evidence that Nafamostat is a potent anti-viral inhibitor in lung cells, a second round of clinical trials in Korea has begun with 10 hospitals participating. [10] Multiple Phase 2/3 [11] [12] [13] and Phase 3 [14] [15] clinical trials for COVID-19 in different countries are ongoing.
Clinical data | |
---|---|
AHFS/ Drugs.com | International Drug Names |
Routes of administration | IV |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C19H17N5O2 |
Molar mass | 347.378 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
Nafamostat mesylate ( INN), a synthetic serine protease inhibitor, it is a short-acting anticoagulant, [1] and is also used for the treatment of pancreatitis. It also has some potential antiviral and anti-cancer properties. [2] Nafamostat is a fast-acting proteolytic inhibitor and used during hemodialysis to prevent the proteolysis of fibrinogen into fibrin. [3] The mechanism of action of Nafamostat is as a slow tight-binding substrate, trapping the target protein in the acyl-enzyme intermediate form, resulting in apparent observed inhibition. [4] [5]
It inhibits a large number of Lys/Arg specific serine proteinases, and is also a tryptase inhibitor, which is implicated in leaking blood vessels which is symptomatic of dengue hemorrhagic fever and of end-stage dengue shock syndrome. [6] It is available in a generic form already used for the treatment of certain bleeding complications in some countries, there are risks of severe complications such as: agranulocytosis, hyperkalemia, and anaphylaxis which must be weighed in non-emergency care. [7] In some countries, it used as a treatment for pancreatitis and pancreatic cancer.[ citation needed]
This drug has been identified as a potential therapy for COVID-19, [8] with clinical trials in Japan possibly set to begin in March 2020. [9] With evidence that Nafamostat is a potent anti-viral inhibitor in lung cells, a second round of clinical trials in Korea has begun with 10 hospitals participating. [10] Multiple Phase 2/3 [11] [12] [13] and Phase 3 [14] [15] clinical trials for COVID-19 in different countries are ongoing.